Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Lymphoid 1

Conditions

Prostatic Neoplasms 58Neoplasm Metastasis 3Prostate Adenocarcinoma 2Neoplasms 2Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Metabolic Syndrome 1Hypogonadism 1Fatty Liver 1Castration-resistant Prostate Cancer Patients with Oligometastases 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Triptorelin Pamoate × Genitourinary × Clear all
NCT05557604 2022-09-28

STUNNIN

Regina Elena Cancer Institute

Phase 2 Recruiting
146 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT02749825 2016-04-25

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Pharmatech

Phase 4 Terminated
41 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡